LOGIN  |  REGISTER
Cue Biopharma
Astria Therapeutics

Streamline Health® Adds Quality Module to Existing eValuator Relationship

October 23, 2024 | Last Trade: US$5.17 0.005 -0.10

ATLANTA, Oct. 23, 2024 (GLOBE NEWSWIRE) --  Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its relationship with an existing eValuator client include the recently released eValuator Quality Module. Streamline expects that this module will increase the SaaS revenues from its eValuator relationship with this client by 25%.

Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. eValuator’s AI-powered pre-bill code auditing analyzes 100% of encounters in real-time, ensuring that providers can accurately capture, bill and ultimately be paid for all the care they provide while avoiding denials. The eValuator quality module enables health systems to prospectively assess the risk score of individual claims and their estimated impact on overall quality measurement in real time. By eliminating manual, post-hoc risk scoring practices, the quality module introduces an industry-leading workflow that allows for correction of coding errors signaled by risk scores.

“We are thrilled to provide additional value to our existing eValuator client by supporting their efforts to better understand the quality of care they’ve provided,” stated Ben Stilwill, President and Chief Executive Officer, Streamline.

About Streamline Health

Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net

 


Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page